COVID-19 pandemic seriously affected European countries. One of the key aspects of managing the epidemic is the timely testing of potentially infected people.
This report summarizes the reimbursement situation for COVID-19 in European countries with established reimbursement framework for in-vitro diagnostic tests (Belgium, France, Germany, Netherlands, Switzerland and Turkey).
The 26-page report answers the following question:
Reimbursement situation is summarized in the countries, where specific reimbursement frameworks exist (Belgium, France, Germany, Netherlands, Switzerland, Turkey)
Brief overview of reimbursement framework in each country is provided
Reimbursement codes and tariffs, testing restrictions and guidelines
Belgium: IVD tests included in the INAMI Nomenclature
France: IVD tests included in the NABM and RIHN Nomenclatures
Germany: IVD tests included in the EBM Nomenclature
Netherlands: Coverage policies by key insurance companies, decisions of Dutch Healthcare Authority and OZP List
Switzerland: IVD tests included in the List of Analyses (Annex 3 of the KLV List)
Turkey: IVD tests included in the Healthcare Implementation Communique